UY34518A - Composiciones que contienen inhibidores de quinasas - Google Patents

Composiciones que contienen inhibidores de quinasas

Info

Publication number
UY34518A
UY34518A UY34518A UY34518A UY34518A UY 34518 A UY34518 A UY 34518A UY 34518 A UY34518 A UY 34518A UY 34518 A UY34518 A UY 34518A UY 34518 A UY34518 A UY 34518A
Authority
UY
Uruguay
Prior art keywords
compositions containing
kinase inhibitors
containing kinase
inhibitors
escanear
Prior art date
Application number
UY34518A
Other languages
English (en)
Inventor
Shi Yi
John M Lipari
Brian E Padden
Lloyd E Dias
Julie K Spence
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34518(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY34518A publication Critical patent/UY34518A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones que comprenden un compuesto que puede inhibir las quinasas, tal como la N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N'-(3-fluorofenil)urea, en una mezcla que comprende (a) un vehículo polimérico soluble en agua farmacéuticamente aceptable y (b) un agente tensioactivo farmacéuticamente aceptable. Estas composiciones son apropiadas para diluirlas con soluciones IV y administrárselas a aquellos sujetos que necesitan ser sometidos a un tratamiento contra un cáncer.
UY34518A 2011-12-14 2012-12-14 Composiciones que contienen inhibidores de quinasas UY34518A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161570679P 2011-12-14 2011-12-14

Publications (1)

Publication Number Publication Date
UY34518A true UY34518A (es) 2013-07-31

Family

ID=47559656

Family Applications (1)

Application Number Title Priority Date Filing Date
UY34518A UY34518A (es) 2011-12-14 2012-12-14 Composiciones que contienen inhibidores de quinasas

Country Status (25)

Country Link
US (1) US20150126545A1 (es)
EP (1) EP2790726A1 (es)
JP (1) JP2015500343A (es)
KR (1) KR20150000869A (es)
CN (1) CN103987406A (es)
AR (1) AR089248A1 (es)
AU (1) AU2012352112A1 (es)
BR (1) BR112014014342A2 (es)
CA (1) CA2857337A1 (es)
CL (1) CL2014001548A1 (es)
CO (1) CO7010829A2 (es)
CR (1) CR20140333A (es)
DO (1) DOP2014000128A (es)
EC (1) ECSP14008671A (es)
HK (1) HK1203368A1 (es)
IL (1) IL232725A0 (es)
MX (1) MX2014007158A (es)
PE (1) PE20142103A1 (es)
PH (1) PH12014501333A1 (es)
RU (1) RU2014128601A (es)
SG (1) SG11201402776WA (es)
TW (1) TW201330850A (es)
UY (1) UY34518A (es)
WO (1) WO2013090666A1 (es)
ZA (1) ZA201404134B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014084A (es) * 2015-05-05 2018-06-20 Psivida Inc Formulaciones de deposito inyectables.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
UY32291A (es) 2008-12-05 2010-07-30 Abbott Lab Inhibidores de quinasa con perfiles de seguridad cyp mejorados
JP5583145B2 (ja) * 2009-03-03 2014-09-03 アルコン リサーチ， リミテッド レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
MX2012014387A (es) * 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.

Also Published As

Publication number Publication date
CR20140333A (es) 2014-09-29
PH12014501333B1 (en) 2014-09-15
ZA201404134B (en) 2015-02-25
SG11201402776WA (en) 2014-06-27
TW201330850A (zh) 2013-08-01
IL232725A0 (en) 2014-07-31
HK1203368A1 (en) 2015-10-30
BR112014014342A2 (pt) 2017-06-13
WO2013090666A1 (en) 2013-06-20
AR089248A1 (es) 2014-08-06
KR20150000869A (ko) 2015-01-05
RU2014128601A (ru) 2016-02-10
US20150126545A1 (en) 2015-05-07
PE20142103A1 (es) 2015-01-11
CO7010829A2 (es) 2014-07-31
AU2012352112A1 (en) 2014-06-12
MX2014007158A (es) 2014-08-29
CA2857337A1 (en) 2013-06-20
CN103987406A (zh) 2014-08-13
DOP2014000128A (es) 2014-08-15
PH12014501333A1 (en) 2014-09-15
CL2014001548A1 (es) 2014-10-10
JP2015500343A (ja) 2015-01-05
EP2790726A1 (en) 2014-10-22
ECSP14008671A (es) 2015-11-30

Similar Documents

Publication Publication Date Title
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY34654A (es) Inhibidores de la beta-secretasa
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
CO7151521A2 (es) Anticuerpos anti-fcrn
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
UY33930A (es) Inhibidores novedosos de quinasas
UY34666A (es) Inhibidores de quinasa a base de ariléter
BR112013007362A2 (pt) composição farmacêutica
UY34365A (es) Compuestos heterociclicos
UY33906A (es) Composiciones herbicidas que comprenden topramezona
UY34582A (es) Anticuerpos anti-cxcr3
UY34442A (es) 2-tiopirimidinonas.
BR112013025866A2 (pt) formulações com viscosidade reduzida
BR112015003294A2 (pt) caldeira de armazenamento
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
CR20150132A (es) Profármacos de aminoquinazolina inhibidora de cinasa
UY4153Q (es) Batería
CL2009001973S1 (es) Mostrador.
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
BR112014000165A2 (pt) dispensador
UY34518A (es) Composiciones que contienen inhibidores de quinasas
UY33905A (es) Inhibidores de la catepsina c

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020